Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Extension Study of Second Dose GBS Trivalent Vaccine in Healthy Non-pregnant Adults
2015-003094-15Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of group b streptococcus trivalent vaccine in Streptococcus agalactiae infection (GBS) and Streptococcus agalactiae sepsis (2 arms), sponsored by GSK. Primary endpoint: Safety of second dose of GBS Trivalent Vaccine. Started Feb 2016; status: completed.
02
Drugs
group b streptococcus trivalent vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)Streptococcus agalactiae sepsis
Beyond the preview
Go deeper on 2015-003094-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003094-15.